Drugs / SY-1365
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03134638 | May 2017 → May 2020 | breast cancer, ovarian cancer | Syros Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SY-1365 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03134638 ↗ |
| Route | Intravenous | “SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle” NCT03134638 ↗ |